{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:16Z","timestamp":1753868656368,"version":"3.41.2"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tumor lysis syndrome (TLS) is a potentially life\u2010threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures. TLS can be managed through hyperhydration, urate\u2010lowering treatments, and a steroid prophase strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aims to explore the impact of fractionated rituximab, an anti\u2010CD20 antibody, on the occurrence and severity of TLS during the initial cycle in patients with aggressive B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data was retrospectively collected from 94 of 186 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 94 patients included in the analysis, the median age was 70. Histologies were diffuse large B\u2010cell lymphoma (75%), Burkitt lymphoma (13%) and high\u2010grade B\u2010cell lymphoma (8%). The majority were at an advanced stage (93%) with a high IPI score (75%). Most patients received anthracycline\u2010containing regimens (72%) and prophylactic allopurinol (83%) and\/or rasburicase (26%). Steroid prophase was administered to 82% of patients. The study identified one clinical TLS case and six laboratory TLS cases. Significant TLS factors included BL histology, elevated baseline LDH (\u27e9500 U\/l), and rasburicase usage. Infusion reactions were rare (3%). Median progression\u2010free survival was 2.6\u2009years, and 2\u2010year overall survival was 33%, irrespective of TLS occurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real\u2010life study, clinical TLS occurrence was low (1%). TLS appeared more frequent in BL but did not impact overall survival. Fractionated initial rituximab dosing in addition to preventive strategies is a feasible approach in preventing clinical TLS, warranting further prospective investigation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1983","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T07:40:11Z","timestamp":1729064411000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive <scp>B\u2010<\/scp>cell lymphoma: Insights from real\u2010life clinical practice"],"prefix":"10.1002","volume":"7","author":[{"given":"Jasmine","family":"Mohamad","sequence":"first","affiliation":[{"name":"Translational Research Centre in Onco\u2010Hematology, Faculty of Medicine University of Geneva and Swiss Cancer Center Leman  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonin","family":"Bouroumeau","sequence":"additional","affiliation":[{"name":"Division of Clinical Pathology, Diagnostic Department Geneva University Hospital  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-3136","authenticated-orcid":false,"given":"Thomas A.","family":"McKee","sequence":"additional","affiliation":[{"name":"Department of Patho\u2010Immunology Geneva University Medical Centre  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mach","sequence":"additional","affiliation":[{"name":"Department of Oncology H\u00f4pitaux Universitaires de Gen\u00e8ve  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaveh","family":"Samii","sequence":"additional","affiliation":[{"name":"Department of Hematology H\u00f4pitaux Universitaires de Gen\u00e8ve  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Chamuleau","sequence":"additional","affiliation":[{"name":"Department Hematology Cancer Center Amsterdam  Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[{"name":"Department Oncology University Hospital Basel and SAKK  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Tamburini","sequence":"additional","affiliation":[{"name":"Translational Research Centre in Onco\u2010Hematology, Faculty of Medicine University of Geneva and Swiss Cancer Center Leman  Geneva Switzerland"},{"name":"Department of Oncology H\u00f4pitaux Universitaires de Gen\u00e8ve  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-4888","authenticated-orcid":false,"given":"No\u00e9mie","family":"Lang","sequence":"additional","affiliation":[{"name":"Translational Research Centre in Onco\u2010Hematology, Faculty of Medicine University of Geneva and Swiss Cancer Center Leman  Geneva Switzerland"},{"name":"Department of Oncology H\u00f4pitaux Universitaires de Gen\u00e8ve  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90254-4"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000054661"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2013.07.001"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90174-N"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1043892"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.emc.2018.04.007"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11575"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv317"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12479"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S103864"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08192.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30145"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050349"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-634394"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-516X.149245"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_27_1","unstructured":"ChamuleauMED StennerF ChituD et al.R\u2010CODOX\u2010M\/R\u2010IVAC versus DA\u2010EPOCH\u2010R in patients with newly diagnosed high\u2010risk Burkitt lymphoma: first results of a multi\u2010center randomized HOVON\/SAKK trial. Paper presented at: 2022 EHA Congress; June 9\u201012 2022; Vienna Austria."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00303"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf134"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.115"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403566"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11612"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01317-3"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006945.pub4"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195609\/10)9:5<965::AID-CNCR2820090517>3.0.CO;2-L"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1725505"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-259333"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13068"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00487-6"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1014366"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30171-5"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0429-3"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1562905"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:31:08Z","timestamp":1730172668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/cnr2.1983"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1983","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2023-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1983"}}